Amphastar Pharmaceuticals Inc (AMPH)

Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare ConferenceMay 27, 2026 6:00 AM
ACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at the 2026 Jefferies Healthcare Conference on Wednesday, June 3, 2026, at 4:55 p.m. ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar Pharmaceuticals, Inc.Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredients, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar.Forward-Looking StatementsAll statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 7, 2026, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.Contact Information:
Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416SOURCE: Amphastar Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026May 7, 2026 4:05 PM
ACCESS NewswireNet revenues of $171.2 million for the three months ended March 31, 2026GAAP net income of $6.4 million, or $0.14 per share, for the first quarterAdjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarterCompany to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended March 31, 2026."In the first quarter of 2026, we continued to strengthen our commercial foundation and core business, highlighted by the approval and subsequent launch of Ipratropium Bromide HFA, while also making meaningful advancements across our pipeline that will support our long-term strategy," said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer. "To begin the year, we broadened our portfolio through an exclusive license agreement for a fully synthetic corticotropin compound. At the same time, we remain committed to investing in our proprietary pipeline and capabilities, which we believe will support sustainable long-term growth." Three Months Ended March 31, 2026 2025 (in thousands, except per share data) Net revenues $171,171 $170,528 GAAP net income $6,420 $25,285 Adjusted non-GAAP net income* $19,478 $36,871 GAAP diluted EPS $0.14 $0.51 Adjusted non-GAAP diluted EPS* $0.42 $0.74 ________________________________* Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled "Non-GAAP Financial Measures" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.First Quarter Results Three Months Ended March 31, Change 2026 2025 Dollars % (in thousands) Net revenues: BAQSIMI® $32,434 $38,355 $(5,921) (15)%Primatene MIST® 29,763 29,051 712 2%Epinephrine 19,213 18,587 626 3%Lidocaine 13,460 13,644 (184) (1)%Glucagon 9,170 20,843 (11,673) (56)%Other products 67,131 50,048 17,083 34%Total net revenues $171,171 $170,528 $643 0%Changes in net revenues as compared to the first quarter of the prior year were primarily driven by:BAQSIMI® sales decreased primarily due to a lower average selling price, as a result of a change in gross-to-net discounts due to changes in chargebacks and rebates and changes to the customer mix, impacting sales of approximately $8.0 million. This decrease was partially offset by an increase in unit volumes, contributing $2.0 million in sales driven by our continued marketing effortsPrimatene MIST® sales increased due to an increase in unit volumesEpinephrine sales increased primarily due to an increase in demand for our epinephrine pre-filled syringe, as a result of other supplier shortages, contributing $4.1 million in sales. This increase was partially offset by a decrease in our epinephrine multi-dose vial product, as a result of increased competition, impacting sales by $3.5 millionGlucagon sales decreased primarily due to a decrease in unit volumes, impacting sales by $6.1 million, as well as a lower average selling price, which impacted sales by $5.6 million, as a result of competition and the continued shift to ready to use glucagon products such as BAQSIMI®Other pharmaceutical product sales increased primarily due to recently launched products including an increase in albuterol sales of $2.8 million, iron sucrose sales of $1.4 million and teriparatide sales of $2.2 million, which we launched in August 2024, August 2025, and December 2025, respectively. An increase in dextrose sales, driven by heightened demand resulting from supplier shortages in the market also positively impacted sales Three Months Ended March 31, Change 2026 2025 Dollars % (in thousands) Net revenues $171,171 $170,528 $643 0%Cost of revenues 100,849 85,277 15,572 18%Gross profit $70,322 $85,251 $(14,929) (18)%as % of net revenues 41.1% 50.0% Changes in the cost of revenues and gross margin were primarily driven by:Lower average selling price for our higher margin products, such as BAQSIMI®, glucagon, phytonadione, and our epinephrine multi-dose vial productIncreased manufacturing expenses due to the expansion of our manufacturing facility in Rancho Cucamonga, CA Three Months Ended March 31, Change 2026 2025 Dollars % (in thousands) Selling, distribution, and marketing $11,927 $11,866 $61 1%General and administrative 18,028 15,996 2,032 13%Research and development 26,737 20,096 6,641 33%General and administrative expenses increased primarily due to an increase in legal expenses, expenses associated with implementing a new ERP system and salary and personnel-related expensesResearch and development expenses increased primarily due to spending for our insulin, inhalation, and proprietary pipeline products. Additionally, we had a $2.0 million upfront payment for the licensing agreement that we entered into with Nanjing Hanxin Pharmaceutical Technology Co., Ltd., during the quarter
Three Months Ended March 31, Change 2026 2025 Dollars % (in thousands) Non-operating expenses: Interest income $2,400 $2,089 $311 15%Interest expense (6,553) (6,286) (267) 4%Other income (expenses), net 575 (2,234) 2,809 (126)%Total non-operating expenses, net $(3,578) $(6,431) $2,853 (44)%The change in non-operating expenses, net, is primarily a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts during the three months ended March 31, 2026.Cash flow provided by operating activities for the three months ended March 31, 2026, was $47.8 million.Pipeline InformationThe Company currently has one abbreviated new drug application ("ANDA") and one biosimilar insulin candidate filed with the FDA targeting products with a combined market size exceeding $1.6 billion, along with two biosimilar products in development targeting products with a market size exceeding $3.7 billion, and two generic products in development targeting products with a market size of over $0.8 billion. This market information is based on IQVIA data for the 12 months ended March 31, 2026. The Company is developing multiple proprietary products with injectable, topical and intranasal dosage forms.The Company's proprietary pipeline also includes four recently in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions.Conference Call InformationThe Company will hold a conference call to discuss its financial results today, May 7, 2026, at 2:00 p.m. Pacific Time.To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website, www.amphastar.com.Non-GAAP Financial MeasuresTo supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which generally excludes amortization expense, share-based compensation, impairment charges, certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance because the Company's management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.Market DataThis press release contains market data that we obtained from industry sources. These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may include projections that are based on a number of other projections. While we believe these assumptions to be reasonable and sound as of the date of this press release, actual results may differ from the projections.About Amphastar Pharmaceuticals, Inc.Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar.Forward Looking StatementsAll statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high-quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.Contact Information:Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416Table I
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations
(Unaudited; in thousands, except per share data) Three Months Ended March 31, 2026 2025 Net revenues $171,171 $170,528 Cost of revenues 100,849 85,277 Gross profit 70,322 85,251 Operating expenses: Selling, distribution, and marketing 11,927 11,866 General and administrative 18,028 15,996 Research and development 26,737 20,096 Total operating expenses 56,692 47,958 Income from operations 13,630 37,293 Non-operating expenses: Interest income 2,400 2,089 Interest expense (6,553) (6,286)Other income (expenses), net 575 (2,234)Total non-operating expenses, net (3,578) (6,431) Income before income taxes 10,052 30,862 Income tax provision 3,632 5,577 Net income $6,420 $25,285 Net income per share: Basic $0.14 $0.53 Diluted $0.14 $0.51 Weighted-average shares used to compute net income per share: Basic 45,322 47,641 Diluted 46,458 49,890 Table II
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except per share data) March 31, December 31, 2026 2025 (unaudited) ASSETS Current assets: Cash and cash equivalents $170,939 $170,177 Restricted cash 235 235 Short-term investments 121,012 112,635 Restricted short-term investments 2,200 2,200 Accounts receivable, net 147,848 143,560 Inventories 170,194 176,890 Income tax refunds and deposits 9,605 17,167 Prepaid expenses and other assets 11,650 13,152 Total current assets 633,683 636,016 Property, plant, and equipment, net 307,231 310,567 Finance lease right-of-use assets 185 221 Operating lease right-of-use assets 71,496 42,931 Goodwill and intangible assets, net 559,623 565,965 Other assets 33,480 31,135 Deferred tax assets 42,464 42,464 Total assets $1,648,162 $1,629,299 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $152,688 $148,348 Income taxes payable 414 239 Current portion of long-term debt 1,671 1,641 Current portion of operating lease liabilities 9,705 7,928 Total current liabilities 164,478 158,156 Long-term reserve for income tax liabilities 5,926 5,926 Long-term debt, net of current portion and unamortized debt issuance costs 609,801 608,749 Long-term operating lease liabilities, net of current portion 65,201 37,684 Other long-term liabilities 29,365 29,979 Total liabilities 874,771 840,494 Commitments and contingencies Stockholders' equity: Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding - - Common stock: par value $0.0001; 300,000,000 shares authorized; 62,134,449 and 44,636,846 shares issued and outstanding, respectively, as of March 31, 2026 and 61,779,883 and 45,645,497 shares issued and outstanding, respectively, as of December 31, 2025 6 6 Additional paid-in capital 543,816 535,380 Retained earnings 673,301 666,881 Accumulated other comprehensive loss (5,736) (5,314)Treasury stock (437,996) (408,148)Total stockholders' equity 773,391 788,805 Total liabilities and stockholders' equity $1,648,162 $1,629,299 Table III
Amphastar Pharmaceuticals, Inc.
Reconciliation of Non-GAAP Measures
(Unaudited; in thousands, except per share data) Three Months Ended March 31, 2026 2025 GAAP net income $6,420 $25,285 Adjusted for: Intangible asset amortization 6,270 6,240 Share-based compensation 9,274 8,393 Litigation provision 1,000 - Income tax provision on pre-tax adjustments (3,486) (3,047)Adjusted non-GAAP net income $19,478 $36,871 Adjusted non-GAAP net income per share: Basic $0.43 $0.77 Diluted $0.42 $0.74 Weighted-average shares used to compute adjusted non-GAAP net income per share: Basic 45,322 47,641 Diluted 46,458 49,890 Three Months Ended March 31, 2026 Selling, General Research Cost of distribution and and Income revenue and marketing administrative development tax provision GAAP $100,849 $11,927 $18,028 $26,737 $3,632 Intangible asset amortization (6,250) - (1) (19) - Share-based compensation (2,456) (360) (5,137) (1,321) - Litigation provision - - (1,000) - - Income tax provision on pre-tax adjustments - - - - 3,486 Non-GAAP $92,143 $11,567 $11,890 $25,397 $7,118 Three Months Ended March 31, 2025 Selling, General Research Cost of distribution and and Income
revenue and marketing administrative development tax provision GAAP $85,277 $11,866 $15,996 $20,096 $5,577 Intangible asset amortization (6,220) - (1) (19) - Share-based compensation (2,338) (313) (4,569) (1,173) - Income tax provision on pre-tax adjustments - - - - 3,047 Non-GAAP $76,719 $11,553 $11,426 $18,904 $8,624 SOURCE: Amphastar Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care ConferenceMay 6, 2026 6:00 AM
ACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the 2026 Bank of America Health Care Conference on Wednesday, May 13, 2026, at 3:00 pm PT. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar Pharmaceuticals, Inc.Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredients, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar.Forward-Looking StatementsAll statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026 and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.Contact Information:
Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416SOURCE: Amphastar Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference

Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare ConferenceApril 6, 2026 6:00 AM
ACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner, SVP of Corp. Communication, will be presenting at the 25th Annual Needham Healthcare Conference on Tuesday, April 14, 2026, at 11:45 am ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar Pharmaceuticals, Inc.Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredients, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar.Forward-Looking StatementsAll statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026 and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.Contact Information:
Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416SOURCE: Amphastar Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference

Amphastar Pharmaceuticals to Present at the Barclays 28th Annual Global Healthcare ConferenceMarch 4, 2026 6:00 AM
ACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / March 4, 2026 / announced today that Bill Peters, CFO, and Dan Dischner, SVP of Corp. Communication, will be presenting at the Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026, at 1:30 pm ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar Pharmaceuticals, Inc.
Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at www.amphastar.com.The Amphastar Pharmaceuticals' logo, and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar Pharmaceuticals, Inc.Forward-Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026 and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.Contact Information:
Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416SOURCE: Amphastar Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: Amphastar Pharmaceuticals to Present at the Barclays 28th Annual Global Healthcare Conference

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025February 26, 2026 4:05 PM
ACCESS NewswireNet revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or $2.03 per share, respectively, for the fourth quarter and fiscal yearAdjusted non-GAAP net income of $34.2 million, or $0.73 per share and $156.6 million, or $3.25 per share, respectively, for the fourth quarter and fiscal yearCompany to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / February 26, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months and full year ended December 31, 2025."2025 underscored Amphastar's evolution into a company focused on both commercial strength and scientific innovation." said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer. "On the commercial side, BAQSIMI® maintained its momentum as a top revenue driver with sustained double-digit growth, while the FDA approvals of our iron sucrose injection and our teriparatide injection demonstrate the depth of our technical capabilities in complex generics and ability to leverage our in-house manufacturing expertise to deliver high-quality, affordable therapies to patients. We also furthered our long-term strategic vision by adding three novel peptides and a fully synthetic corticotropin compound to expand our presence in oncology, ophthalmology, and immunology. As we look ahead to 2026, we remain committed to advancing these programs, securing upcoming approvals, and scaling our U.S. based manufacturing to support the next phase of our growth." Three Months Ended Year Ended December 31, December 31, 2025 2024 2025 2024 (in thousands, except per share data) Net revenues $183,105 $186,523 $719,887 $731,967 GAAP net income $24,429 $37,964 $98,094 $159,519 Adjusted non-GAAP net income* $34,158 $47,237 $156,618 $200,806 GAAP diluted EPS $0.51 $0.74 $2.03 $3.06 Adjusted non-GAAP diluted EPS* $0.73 $0.92 $3.25 $3.86 _____________________________* Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled "Non-GAAP Financial Measures" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.Fourth Quarter Results Three Months Ended December 31, Change 2025 2024 Dollars % (in thousands) Product revenues, net: BAQSIMI® $46,708 $41,792 $4,916 12%Primatene MIST® 27,930 28,935 (1,005) (3)%Epinephrine 17,087 18,698 (1,611) (9)%Lidocaine 14,904 14,397 507 4%Glucagon 14,081 25,619 (11,538) (45)%Other products 62,395 57,537 4,858 8%Total product revenues, net $183,105 $186,978 $(3,873) (2)%Other revenues - (455) 455 100%Total net revenues $183,105 $186,523 $(3,418) (2)%Changes in product revenues, net as compared to the fourth quarter of the prior year were primarily driven by:BAQSIMI® sales increased primarily due to an increase in unit volumes, as a result of our continued marketing efforts in the United StatesPrimatene MIST® sales decreased due to lower unit volumesEpinephrine sales decreased due to lower unit volumes, as well as a lower average selling price of the multi-dose vial product, impacting sales by $2.8 million and $1.5 million, respectively, as a result of increased competition. This trend was partially offset by an increase in unit volumes for our epinephrine pre-filled syringe, as a result of an increase in demand caused by shortages from other suppliers during the quarterGlucagon sales decreased primarily due to a lower average selling price, impacting sales by $10.2 million, as well as a decrease in unit volumes, impacting sales by $1.3 million, as a result of competition and the continued shift to ready to use glucagon products such as BAQSIMI®Other pharmaceutical product sales changes were primarily due to an increase in sales of albuterol of $4.2 million and iron sucrose sales of $2.0 million, which we launched in August 2024 and August 2025, respectively. This increase was partially offset by a decrease in unit volumes of dextrose, primarily due to increased competitionOther revenues were zero in the fourth quarter of 2025, as we completed the assumption of distribution responsibilities globally for BAQSIMI® at the beginning of 2025, with all of BAQSIMI® related revenues in the current period being recognized in product revenues, net Three Months Ended December 31, Change 2025 2024 Dollars % (in thousands) Net revenues $183,105 $186,523 $(3,418) (2)%Cost of revenues 97,435 99,875 (2,440) (2)%Gross profit $85,670 $86,648 $(978) (1)%as % of net revenues 46.8% 46.5% Changes in the cost of revenues and gross margin were primarily driven by:Increase in sales of BAQSIMI® and sales of iron sucrose, which we launched in August 2025, as well as cost control efforts across the businessThis was partially offset by a decrease in pricing of glucagon and our epinephrine multi-dose vial product Three Months Ended December 31, Change 2025 2024 Dollars % (in thousands) Selling, distribution, and marketing $10,279 $10,424 $(145) (1)%General and administrative 16,471 12,938 3,533 27%Research and development 23,314 18,142 5,172 29%General and administrative expenses increased primarily due to an increase in salary and personnel-related expenses, legal expenses and expenses related to the implementation of a new ERP systemResearch and development expenses increased primarily due to an increase in clinical trial expense, primarily related to our insulin and inhalation pipeline products, as well as an increase in material and supplies for our insulin pipeline product Three Months Ended December 31, Change 2025 2024 Dollars % (in thousands) Non-operating expenses: Interest income $2,423 $2,292 $131 6%Interest expense (6,630) (6,425) (205) 3%Other income, net 515 2,951 (2,436) (83)%Total non-operating expenses, net $(3,692) $(1,182) $(2,510) 212%The change in non-operating expenses, net, is primarily due to a change in other income, net, as a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts during the three months ended December 31, 2025.Year-End Results Year Ended December 31, Change 2025 2024 Dollars % (in thousands) Product revenues, net: BAQSIMI® $185,358 $126,898 $58,460 46%Primatene MIST® 108,669 102,012 6,657 7%Epinephrine 70,643 94,090 (23,447) (25)%Glucagon 69,084 108,319 (39,235) (36)%Lidocaine 56,479 55,854 625 1%Other products 229,654 225,641 4,013 2%Total product revenues, net $719,887 $712,814 $7,073 1%Other revenues - 19,153 (19,153) (100)%Total net revenues $719,887 $731,967 $(12,080) (2)%Changes in product revenues, net as compared to the prior fiscal year were primarily driven by:BAQSIMI® sales increased primarily due to an increase in unit volumes, as a result of an expanded marketing effort in the United States; total sales of BAQSIMI® grew 12% from the prior year including prior year sales by Eli Lilly and Company, or Lilly, which was accounted for in Other revenuesPrimatene MIST® sales increased due to an increase in unit volumes driven by our continued marketing effortsEpinephrine sales decreased due to a decrease in unit volumes, impacting sales of $13.4 million, as well as a lower average selling price, which impacted sales of $10.0 million, primarily as a result of increased competition for our multi-dose vial productGlucagon sales decreased primarily due to a lower average selling price, impacting sales by $24.3 million, as well as a decrease in unit volumes, impacting sales by $14.9 million, as a result of competition and the continued shift to ready to use glucagon products such as BAQSIMI®Other pharmaceutical product sales changes were primarily due to an increase in sales of albuterol of $14.7 million and iron sucrose sales of $4.4 million, which were launched in August 2024 and August 2025, respectively, as well as an increase in sales of sodium bicarbonate and atropine due to an increase in demand caused by other supplier shortages. This increase was partially offset by a decrease in sales of enoxaparin of $9.9 million and dextrose of $9.6 million due to increased competitionOther revenues were zero in the year ended December 31, 2025 as we completed the assumption of distribution responsibilities globally for BAQSIMI® at the beginning of 2025, with all of BAQSIMI® related revenues in the current period being recognized in Product revenues, net. The other revenues in the year ended December 31, 2024 consisted of $19.2 million in BAQSIMI® sales made by Lilly on our behalf under the Transition Service Agreement ("TSA"), and was net of $18.4 million in cost of sales and other expenses Year Ended December 31, Change 2025 2024 Dollars % (in thousands) Net revenues $719,887 $731,967 $(12,080) (2)%Cost of revenues 363,830 358,112 5,718 2%Gross profit $356,057 $373,855 $(17,798) (5)%as % of net revenues 49.5% 51.1% Changes in the cost of revenues and gross margin were primarily driven by:Decrease in other revenues related to Lilly's sales of BAQSIMI® under the TSA, which were recorded net of cost of sales and other expenses; as we assumed distribution of BAQSIMI® to all of our customers by the beginning of 2025. We recorded those sales in product revenues and cost of sales separatelyLower pricing of glucagon and our epinephrine multi-dose vial product, both of which are higher-margin productsCost control efforts across the business partially offset the impact of pricing declines Year Ended December 31, Change 2025 2024 Dollars % (in thousands) Selling, distribution, and marketing $43,885 $37,802 $6,083 16%General and administrative 85,925 56,720 29,205 51%Research and development 85,844 73,914 11,930 16%Selling, distribution, and marketing expenses increased primarily due to the expansion of our sales and marketing efforts related to BAQSIMI®, including expenses related to our co-promotion contract with MannKind, and sales efforts related to Primatene MIST®General and administrative expenses increased primarily due to a legal settlement, which increased expenses by $23.1 millionResearch and development expenses increased primarily due to the $6.0 million upfront payment for the licensing agreement that we entered into with Nanjing Anji Biotechnology Co., Ltd. ("Anji"), during the year. Additionally, we had an increase in clinical trial expense, primarily related to our insulin and inhalation pipeline products, as well as an increase in depreciation expense. This was partially offset by a decrease in materials and supply expenses Year Ended December 31, Change 2025 2024 Dollars % (in thousands) Non-operating expenses: Interest income $8,679 $10,612 $(1,933) (18)%Interest expense (25,481) (30,343) 4,862 (16)%Other income, net 23 4,076 (4,053) (99)%Total non-operating expenses, net $(16,779) $(15,655) $(1,124) 7%The change in non-operating expenses, net is primarily a result of:A decrease in interest income resulting from a decrease in interest rates on our cash and investments accountsA decrease in interest expense as a result of the repayment of the mortgage loan with East West Bank, as well as the accretion of the interest on the deferred payment for BAQSIMI®, both of which were paid in full in June 2024A change to other income, net, primarily as a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts during the year ended December 31, 2025Cash flow provided by operating activities for the year ended December 31, 2025, was $156.1 million.Pipeline InformationThe Company currently has one abbreviated new drug application ("ANDA") and one biosimilar insulin candidate filed with the FDA targeting products with a combined market size exceeding $1.7 billion, along with two biosimilar products in development targeting products with a market size exceeding $3.7 billion, and two generic products in development targeting products with a market size of over $1 billion. This market information is based on IQVIA data for the 12 months ended December 31, 2025. The Company is developing multiple proprietary products with injectable, topical and intranasal dosage forms.The Company's proprietary pipeline also includes four recently in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions.Conference Call InformationThe Company will hold a conference call to discuss its financial results today, February 26, 2026, at 2:00 p.m. Pacific Time.To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website at www.amphastar.com.Non-GAAP Financial MeasuresTo supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which generally excludes amortization expense, share-based compensation, impairment charges, expenses related to our acquisition of BAQSIMI®, certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance because the Company's management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.Market DataThis press release contains market data that we obtained from industry sources. These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may include projections that are based on a number of other projections. While we believe these assumptions to be reasonable and sound as of the date of this press release, actual results may differ from the projections.About Amphastar Pharmaceuticals, Inc.Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar.Forward-Looking StatementsAll statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high-quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.Contact Information:Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416Table I
Amphastar Pharmaceuticals, Inc.
Consolidated Statement of Operations
(in thousands, except per share data) Three Months Ended Year Ended December 31, December 31, 2025 2024 2025 2024 Net revenues: Product revenues, net $183,105 $186,978 $719,887 $712,814 Other revenues - (455) - 19,153 Total net revenues 183,105 186,523 719,887 731,967 Cost of revenues 97,435 99,875 363,830 358,112 Gross profit 85,670 86,648 356,057 373,855 Operating expenses: Selling, distribution, and marketing 10,279 10,424 43,885 37,802 General and administrative 16,471 12,938 85,925 56,720 Research and development 23,314 18,142 85,844 73,914 Total operating expenses 50,064 41,504 215,654 168,436 Income from operations 35,606 45,144 140,403 205,419 Non-operating expenses: Interest income 2,423 2,292 8,679 10,612 Interest expense (6,630) (6,425) (25,481) (30,343)Other income, net 515 2,951 23 4,076 Total non-operating expenses, net (3,692) (1,182) (16,779) (15,655) Income before income taxes 31,914 43,962 123,624 189,764 Income tax provision 7,485 5,998 25,530 29,672 Income before equity in losses of unconsolidated affiliate 24,429 37,964 98,094 160,092 Equity in losses of unconsolidated affiliate - - - (573) Net income $24,429 $37,964 $98,094 $159,519 Net income per share: Basic $0.53 $0.79 $2.10 $3.29 Diluted $0.51 $0.74 $2.03 $3.06 Weighted-average shares used to compute net income per share: Basic 45,907 47,975 46,743 48,429 Diluted 47,164 51,310 48,215 52,058 Table II
Amphastar Pharmaceuticals, Inc.
Consolidated Balance Sheets
(in thousands, except share data) December 31, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $170,177 $151,609 Restricted cash 235 235 Short-term investments 112,635 70,036 Restricted short-term investments 2,200 2,200 Accounts receivable, net 143,560 136,289 Inventories 176,890 153,741 Income tax refunds and deposits 17,167 1,747 Prepaid expenses and other assets 13,152 18,214 Total current assets 636,016 534,071 Property, plant, and equipment, net 310,567 297,345 Finance lease right-of-use assets 221 383 Operating lease right-of-use assets 42,931 46,899 Goodwill and intangible assets, net 565,965 590,660 Long-term investments - 10,996 Other assets 31,135 25,992 Deferred tax assets 42,464 71,124 Total assets $1,629,299 $1,577,470 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $148,348 $157,057 Income taxes payable 239 9,664 Current portion of long-term debt 1,641 234 Current portion of operating lease liabilities 7,928 6,804 Total current liabilities 158,156 173,759 Long-term reserve for income tax liabilities 5,926 6,957 Long-term debt, net of current portion and unamortized debt issuance costs 608,749 601,630 Long-term operating lease liabilities, net of current portion 37,684 41,881 Other long-term liabilities 29,979 20,945 Total liabilities 840,494 845,172 Commitments and contingencies Stockholders' equity: Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding - - Common stock: par value $0.0001; 300,000,000 shares authorized; 61,779,883 and 45,645,497 shares issued and outstanding, respectively, as of December 31, 2025 and 60,847,124 and 47,617,691 shares issued and outstanding, respectively, as of December 31, 2024 6 6 Additional paid-in capital 535,380 505,400 Retained earnings 666,881 568,787 Accumulated other comprehensive loss (5,314) (9,181)Treasury stock (408,148) (332,714)Total stockholders' equity 788,805 732,298 Total liabilities and stockholders' equity $1,629,299 $1,577,470 Table III
Amphastar Pharmaceuticals, Inc.
Reconciliation of Non-GAAP Measures
(in thousands, except per share data) Three Months Ended Year Ended December 31, December 31, 2025 2024 2025 2024 GAAP net income $24,429 $37,964 $98,094 $159,519 Adjusted for: Intangible asset amortization 6,270 6,179 25,048 24,718 Share-based compensation 6,205 5,632 27,277 24,368 Expenses related to BAQSIMI® acquisition - - - 3,651 Litigation provision - - 23,147 - Income tax provision on pre-tax adjustments (2,746) (2,538) (16,948) (11,450)Adjusted non-GAAP net income $34,158 $47,237 $156,618 $200,806 Adjusted non-GAAP net income per share: Basic $0.75 $0.99 $3.35 $4.15 Diluted $0.73 $0.92 $3.25 $3.86 Weighted-average shares used to compute adjusted non-GAAP net income per share: Basic 45,907 47,975 46,743 48,429 Diluted 47,164 51,310 48,215 52,058 Three Months Ended December 31, 2025 Selling, General Research Non-operating Cost of distribution and and (expenses) Income revenue and marketing administrative development income, net tax provision GAAP $97,435 $10,279 $16,471 $23,314 $(3,692) $7,485 Intangible asset amortization (6,250) - (1) (19) - - Share-based compensation (1,193) (290) (4,142) (580) - - Income tax provision on pre-tax adjustments - - - - - 2,746 Non-GAAP $89,992 $9,989 $12,328 $22,715 $(3,692) $10,231 Three Months Ended December 31, 2024 Selling, General Research Non-operating Cost of distribution and and (expenses) Income revenue and marketing administrative development income, net tax provision GAAP $99,875 $10,424 $12,938 $18,142 $(1,182) $5,998 Intangible asset amortization (6,160) - - (19) - - Share-based compensation (1,159) (286) (3,682) (505) - - Income tax provision on pre-tax adjustments - - - - - 2,538 Non-GAAP $92,556 $10,138 $9,256 $17,618 $(1,182) $8,536 Year Ended December 31, 2025 Selling, General Research Non-operating Cost of distribution and and (expenses) Income revenue and marketing administrative development income, net tax provision GAAP $363,830 $43,885 $85,925 $85,844 $(16,779) $25,530 Intangible asset amortization (24,968) - (3) (77) - - Share-based compensation (6,205) (1,215) (16,919) (2,938) - - Litigation provision - - (23,147) - - - Income tax provision on pre-tax adjustments - - - - - 16,948 Non-GAAP $332,657 $42,670 $45,856 $82,829 $(16,779) $42,478 Year Ended December 31, 2024 Selling, General Research Non-operating Cost of distribution and and (expenses) Income revenue and marketing administrative development income, net tax provision GAAP $358,112 $37,802 $56,720 $73,914 $(15,655) $29,672 Intangible asset amortization (24,639) - (4) (75) - - Share-based compensation (5,742) (1,063) (14,921) (2,642) - - Expenses related to BAQSIMI® acquisition - - - - 3,651 - Income tax provision on pre-tax adjustments - - - - - 11,450 Non-GAAP $327,731 $36,739 $41,795 $71,197 $(12,004) $41,122 SOURCE: Amphastar Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025

Amphastar Announces FDA Approval for Ipratropium Bromide HFAFebruary 24, 2026 6:00 AM
ACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation. The FDA determined that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is bioequivalent and therapeutically equivalent to Boehringer Ingelheim's Atrovent® HFA Inhalation Aerosol.Additionally, the FDA has confirmed that this product is eligible for 180-days of generic drug exclusivity for Ipratropium Bromide HFA Inhalation Aerosol as we were the first ANDA applicant with Paragraph IV certification. This exclusivity period will begin on the first day that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is commercially launched."We are excited to announce FDA approval of Ipratropium Bromide HFA Inhalation Aerosol, reinforcing the strength of our integrated R&D and manufacturing model and demonstrating our ability to deliver complex, high-value generics," said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer. "We expect this launch to contribute meaningfully to our respiratory portfolio and to further strengthen our long-term growth strategy, capabilities and commitment to delivering impactful therapies to patients as we increase our efforts on the development of proprietary pipeline candidates."Ipratropium is an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. According to IQVIA, the U.S. sales for Atrovent® HFA were approximately $112 million for the 12 months ended December 31, 2025.Amphastar plans to launch its Ipratropium Bromide HFA Inhalation Aerosol, previously referred to as AMP-007, early in the second quarter of 2026.Pipeline InformationThe Company currently has one ANDA and one biosimilar insulin filed with the FDA targeting products with a combined market size of over $1.7 billion, along with two biosimilar products in development targeting products with a market size exceeding $3.7 billion, and two generic products in development targeting products with a market size of over $1 billion. This market information is based on IQVIA data for the 12 months ended December 31, 2025. The Company is developing multiple proprietary products with injectable and intranasal dosage forms.The Company's proprietary pipeline also includes four recently in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions.About Amphastar Pharmaceuticals, Inc.Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar ®, BAQSIMI ®, Primatene MIST ®, REXTOVY ®, Amphadase ®, AmpsilogTM and Cortrosyn ®, are the property of Amphastar.Forward-Looking StatementsAll statements in this press release referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high-quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025, in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI ®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.Contact Information:Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416SOURCE: Amphastar Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: Amphastar Announces FDA Approval for Ipratropium Bromide HFA

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026February 20, 2026 6:00 AM
ACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2025 ended December 31, 2025, after the market closes on Thursday, February 26, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll-free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our manufacturing in-house expertise, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025, in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.CONTACT:
Bill Peters
Chief Financial Officer
(909) 476-3416SOURCE: Amphastar Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026

I've bought some AMPH at $31. Great products and decent numbers. Hoping for a move back up to the low $40's.

AMPH buy 42.3299

https://finance.yahoo.com/quote/AMPH/profile?p=AMPH

https://www.barchart.com/stocks/quotes/AMPH

https://finviz.com/quote.ashx?t=AMPH

https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=AMPH

https://stockcharts.com/c-sc/sc?chart=AMPH,uu[e,a]dhclyiay[uu][pb5!b10!b50!b100!b200!d20,2!h.02,.20!f][vb5!b20][iut!lv8!lk9!LE12,26,9!ll14!la6,13,5!la8,17,9!la12,26,9!uc14!ub14!ub6!lo!lp7,3!lh9,3!LI14,3!lxa!ld8!lq!lg14!lf14][j20444984,y]&r=3555b

https://www.barchart.com/etfs-funds/quotes/AMPH/technical-chart?plot=CANDLE&volume=toAMPH&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=TREND&sym=AMPH&grid=1&height=500&studyheight=100&timeframe=2%20Months




normal chart









log chart









normal chart








log chart

AMPH 50/200sma crossed here...Nice bullish sign.

fda approval

Gearing up for another amazing surprise quarter of positive earnings!!! Always a nice push down just before the after earnings report POP!

reading my friend, their drug helper going on shelf item, any thoughts ?????

China has several generic-insulin products already on the market.

Do you see them investing in China to develop generic insulin since China has a huge diabetes problem?

Squeezing up! I love it

Momenta, Sandoz allowed to broaden claims over quality test patent

A federal judge has allowed Momenta Pharmaceuticals and Sandoz Inc to broaden a lawsuit accusing Amphastar Pharmaceuticals of infringing a patent on quality control methods used in making the blood thinner enoxaparin, the generic form of French drug maker Sanofi's Lovenox.

U.S. District Judge Nathaniel Gorton in Massachusetts said Tuesday that Momenta and Sandoz could add new infringement allegations to their complaint in light of a ruling last November by the U.S. Court of Appeals for the Federal Circuit that California-based Amphastar is not protected by a safe harbor provision in the patent law.

http://www.reuters.com/article/health-patent-idUSL1N19F0C7

Ampha market cap is about 750 M and is valued way less than the damage they caused. Momenta was making about a 1 M a day on lovonox before the Ampha debacle. bp

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123595244

AMPH is not a start-up, but it has trouble making money, evidently. The past 3 quarters have basically been at break-even.

Update on Lovenox patent case: #msg-113632332.

No issue.

IT IS 32 MILLION FROM NOW TO END OF 2015
IT IS THE 2ND TO LAST QUESTION

will not respond again.

http://www.amphastar.com/

They did give a number for their MANNKIND production only that it was very profitable. Your wrong. Sorry. You need to listen again.

You just did not hear it ....
call AMPH and you will find out they did.
If I owned stock I would call ....

They did not give any dollar figure for their sales to MannKind.

This EPS info is wrong.
Sorry ....

Phaeton
Did you catch only 32 million sales to MNKD in 2015
in the conf call ?

Share buyback program for AMPH

On November 6, 2014, the Company's Board of Directors authorized a $10.0 million share buyback program, which is expected to continue for an indefinite period. The primary goal of the program is to offset dilution created by the Company's equity compensation programs.

Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means, as determined by the Company's management and in accordance with the requirements of the Securities and Exchange Commission.

Do you have a phone number for that call you posted ?

Phaeton
Is that what you are going to do ?

Dump all you mannkind and buy amph.

AMPH NOV 28, 2014

Amphastar Pharmaceuticals, Inc. (AMPH) is a specialty pharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on AMPH’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Amphastar Pharmaceuticals could be a solid choice for investors.Current Quarter Estimates for AMPH In the past 30 days, 1 estimate has gone higher for Amphastar Pharmaceuticals while none has gone lower in the same time period. The trend has been pretty favorable too, with loss estimates narrowing down from 11 cents a share 30 days ago, to 6 cents today, a move of over 45.5%.Current Year Estimates for AMPH Meanwhile, Amphastar Pharmaceuticals’ current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to 1 moving lower. The loss estimate trend has also seen a boost for this time frame, narrowing down from 16 cents per share 30 days ago to 14 cents per share today, an improvement of 12.5%.Bottom Line The stock has also started to move higher lately, adding 6.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.

AMPH 30 This chart has gotten a little ahead of it self . IMHO

AMPH M

AMPH D

I went back and listened to the Amphstar call again. They said that they had 9 billion in the pipeline on generic products using their inhalation side of their business. They particularly stated that they were working on PARTICULE ENGINEERING of complex molecules. They view their inhalation side of the business with a higher value. That Amphstar would do the science side and that a Pharm partner would do the sales and marketing side. Makes me wonder if they are going to use the Technosphere on some generic drugs. I would encourage you go listen to the call and give your opinion. I found the call interesting. this part was in the last 7 or 8 mins of the call. One of the generics mentioned was Advir

Piper Jaffery call this morning.

Amphstar said on their call today, That they became instantly profitable based on the deal they made to supply insulin to mannKind. I missed part of the call so I don't know if they talked earlier about that purchased by mankind but I thought it was good that it was mentioned about their profitability was based on their contract and future sales to MannKind. They also stated that they had some new drugs in their pipeline where they would be partnering with another firm. Did not mention Mannkind but the decussion was on particle molucules and peptides involving inhalation drugs. I thought it was a very interesting call. I will try and go back and listen to the 5 mins that I missed when the call is reposted.

I'm interested due to their naloxone product- I can't figure out what was with that mid-day spike today but I'm trying to get a feeling for this one

I do a little.

Anyone been following this company?

Go check out the Friends of MannKind board on this site.
If you want information on the partner to AMPH. Or post information regarding MNKD partnership with MNKD here on this board.

Home > Boards > Free Zone > User's Groups >
Friends of MannKInd

Forbes on Fox just recommended buying AMPH. Funny how people like the supplier of insulin enough but not the producer of Afrezza.

good posting on AMPHASTAR partner.
Moved from the MNKD Board.

Ha Ha Ha we are trying to be a POS penny stock like the ones you follow. Perhaps our bad Karma will get us to that position. But I am betting that won't happen. Perhaps today its ugly but let's see where we are this time next year.

A good Doctor had these comments on another message board. Perhaps he see's the future of Diabetic treatment.

Let me give you the perspective of a primary care physician. Sanofi tried for a long time to push Apidra to us. There was not enough of a difference between it and our standards, Novolog and Humalog, to convince many to change, so the sales with primary care docs fell flat. As a result Sanofi now positions Apidra as the preferred insulin for pumps and they have been somewhat successful with that marketing strategy. Afrezza on the other hand is a totally different product. It is inhaled, not just another shot. And it does not come with a complicated delivery device like Exubera did. Have you ever seen the delivery device for Exubera? It was extremely complicated. Despite being instructed in its use on several occasions I could see that it was far too complicated for the average patient and therefore never prescribed Exubera. The Dreamboat on the other hand is extremely simple and requires less instruction time than even the simplest of the insulin pens. And yes, I have actually had a Dreamboat in my hands so I know what I am talking about. This will save me time in my office, something that is going away quickly as the practice of medicine becomes more and more complex thanks to all the regulations from Uncle Sam and the other insurance companies. The reason that Exubera failed was the delivery device first of all and the fact that it was in milligrams, not units (and the mg to unit conversion was not even 1:1, too complicated). All a patient has to do with the Dreamboat is open it up, insert a cartridge, close it, and breathe in deeply. And every 2 weeks just drop the used Dreamboat in a trash can and pull out a fresh clean Dreamboat. No cleaning, no replacing parts, etc, etc, etc that were required with the Exubera bong. And it will fit in the pocket of any man, something that a man could actually do with the Exubera device but resulted in him getting all sorts of crude comments from those around him.
For those of you who think for whatever reason that Afrezza will fail you should think again. I have been doing this a long, long time. This is going to be a game changer. In diabetes for now. But in many medical fields in the coming years. I am not pumping as you call it on this board, I am simply looking at what goes on in an average primary care practice. I am sure that there will be criticisms of this post. That seems to occur for most posts that look at the good side of Afrezza. Bring it on. And mark my word. And mark this post. (Last 2 sentences thrown in on purpose to raise the hair on the back of the necks of those who get all upset when they read those words.)

I look forward to my investment returning me a a great increase in PPS and the game changer it brings to the Diabetic community. So if MannKind is not at $15.00 this time next year its a failure. If the company is not purchased by SNY for $30.00 per share next year its a failure. But at least I have enjoyed the fact that long term this product will benefit Millions of diabetics in the USA and the world. Mark my word.

Mannkind is not a plane crash.

Yep be we will be rising soon on MNKD. Should have bought this at 9.00 instead of buying more of MannKind. But I bet we all will be ok. In DC wed - Sunday. Up for coffee in sat or Sunday

Silent riser I love it!

Only what is know publicly. MannKind will be buying a lot of insulin which will be sold by Sanofi.

Can you go into more detail about the "Mannkind contract" that you mentioned?

Should have reseved some extra cash for AMPH. Seems to be moving in the right direction. You have to think that most of it is because of the MannKind contract.

Definitely a good stock to keep an eye on With it's ties to mannkind this will be a winner

$AMPH DD Notes ~ http://www.ddnotesmaker.com/AMPH

bullish

$AMPH recent news/filings

## source: finance.yahoo.com

Tue, 26 Aug 2014 10:55:03 GMT ~ Increased Earnings Estimates Seen for Amphaster Pharmaceuticals (AMPH): Can It Move Higher?


read full: http://finance.yahoo.com/news/increased-earnings-estimates-seen-amphaster-105503341.html
*********************************************************

Mon, 25 Aug 2014 10:37:10 GMT ~ Why Amphastar Pharmaceuticals (AMPH) Stock Might be a Great Pick


read full: http://finance.yahoo.com/news/why-amphastar-pharmaceuticals-amph-stock-103710002.html
*********************************************************

Wed, 13 Aug 2014 20:17:38 GMT ~ AMPHASTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/140813/amph10-q.html
*********************************************************

Tue, 12 Aug 2014 20:17:56 GMT ~ Amphastar Pharmaceuticals Reports Revenues of $49.0 Million for the Second Quarter Ended June 30, 2014

[at noodls] - Previous Release RANCHO CUCAMONGA, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) ("Amphastar" or the "Company") today reported results for ...

read full: http://www.noodls.com/view/95D663AB3AE09C53FF0E0DB8C7D9D337DA11E846
*********************************************************

Tue, 12 Aug 2014 20:02:10 GMT ~ AMPHASTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen


read full: http://biz.yahoo.com/e/140812/amph8-k.html
*********************************************************


$AMPH charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$AMPH company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/AMPH/company-info
Ticker: $AMPH
OTC Market Place: Not Available
CIK code: not found
Company name: Amphastar Pharmaceuticals, Inc.
Incorporated In: USA


$AMPH share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$AMPH extra dd links

Company name: Amphastar Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=AMPH+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=AMPH+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=AMPH+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/AMPH/news - http://finance.yahoo.com/q/h?s=AMPH+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/AMPH/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/AMPH/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=AMPH+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/AMPH
DTCC (dtcc.com): http://search2.dtcc.com/?q=Amphastar+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Amphastar+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Amphastar+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/AMPH
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/AMPH/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/AMPH/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=AMPH&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=AMPH
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/AMPH/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=AMPH+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=AMPH+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=AMPH
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=AMPH
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=AMPH+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/AMPH/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=AMPH+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/AMPH.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=AMPH
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/AMPH/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/AMPH
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/AMPH
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/AMPH:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=AMPH
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=AMPH



$AMPH DD Notes ~ http://www.ddnotesmaker.com/AMPH